Overview

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Status:
RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborator:
Shanghai Pharmaceuticals Holding Co., Ltd